Conditions: End Stage Renal Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 200
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety and efficacy of induction therapy with Thymoglobulin in comparison with IL2 receptor antagonists (daclizumab or basiliximab).

Detailed description:
A 12 month, prospective, randomized, single center, open-label study to evaluate the safety and efficacy of Rabbit anti-thymocyte globulin versus IL2 receptor antagonists in combination with tacrolimus, corticosteroids and mycophenolate mofetil in a predominantly high risk kidney transplant population.

Arms:
arm 1: Subjects receiving Thymoglobulin as induction agent in renal transplantation arm 2: subject who will receive daclizumab or basiliximab as induction agent in renal transplantation

Interventions: intervention 1: Rabbit Antithymocyte globulin intervention 2: Daclizumab
Intervention descriptions: intervention 1: 1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4 intervention 2: 1.0 mg/kg pre-op and 1.0 mg/kg on Day 7

Protocol document: